Metastatic dormancy and progression in thyroid cancer: Targeting cells in the metastatic frontier

Thyroid

Volumn 21, Issue 5, 2011, Pages 487-492

  Ringel, Matthew D ^a,b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b 445D McCampbell Hall ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; KISSPEPTIN; KISSPEPTIN 1; NUCLEOSIDE DIPHOSPHATE KINASE NM23; RCAN 1 PROTEIN; RCAN 2 PROTEIN; RCAN 3 PROTEIN; RCAN 4 PROTEIN; TETRASPANIN; TETRASPANIN KAI 1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CANCER MODEL; DIFFERENTIATED THYROID CANCER; EPITHELIAL MESENCHYMAL TRANSITION; EXOSOME; EXTRACELLULAR MATRIX; GENE MUTATION; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; METASTASIS; METASTASIS INHIBITION; METASTASIS POTENTIAL; METASTATIC DORMANCY; ONCOGENE; PRIORITY JOURNAL; THYROID CANCER; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; EXOSOMES; EXTRACELLULAR MATRIX; HUMANS; IMMUNE SYSTEM; MEDICAL ONCOLOGY; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENES; THYROGLOBULIN; THYROID NEOPLASMS;

EID: 79957467074     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2011.2121     Document Type: Article

References (63)

1. Paget S 1889 The distribution of secondary growths in cancer of the breasts. Lancet 1:571-573.
2. Aguirre-Ghiso JA 2007 Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7:834-846. (Pubitemid 350006258)
3. Nguyen DX, Bos PD, Massague J 2009 Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9:274-284.
4. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, Yang Q, Bishop JM, Contag CH, Felsher DW 2004 MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431:1112-1117. (Pubitemid 39472236)
5. Gardner RE, Tuttle RM, Burman KD, Haddady S, Truman C, Sparling YH, Wartofsky L, Sessions RB, Ringel MD 2000 Prognostic importance of vascular invasion in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg 126:309-312. (Pubitemid 30140383)
6. Tsuji T, Ibaragi S, Hu G-F 2009 Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res 69:7135-7139.
7. Mani SA, Guo W, Liao M-J, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA 2008 The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704-715. (Pubitemid 351636299)
8. Singh A, Settleman J EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29:4741-4751.
9. Klein CA, Hölzel D 2006 Systemic cancer progression and tumor dormancy: mathematical models meet single cell genomics. Cell Cycle 5:1788-1798. (Pubitemid 44435321)
10. Podsypanina K, Du YC, Jechlinger M, Beverly LJ, Hambardzumyan D, Varmus H 2008 Seeding and propagation of untransformed mouse mammary cells in the lung. Science 321:1841-1844.
11. Kusumbe AP, Bapat SA 2009 Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res 69:9245-9253.
12. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry WT Jr, Carter BS, Krichevsky AM, Breakefield XO 2008 Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10:1470-1476.
13. Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, Tuttle RM, Drucker W, Larson SM 2006 Real-time prognosis for metastatic thyroid carcinoma based on 2- [18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91:498-505. (Pubitemid 43236915)
14. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M 2006 Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91:2892-2899. (Pubitemid 44271732)
15. Xing M 2007 BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28:742-762. (Pubitemid 350294294)
16. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP 1993 High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91:179-184. (Pubitemid 23037270)
17. Paes JE, Ringel MD 2008 Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol Metab Clin North Am 37:375-387. (Pubitemid 351698084)
18. Ringel MD 2009 Molecular markers of aggressiveness of thyroid cancer. Curr Opin Endocrinol Diabetes Obes 16: 361-366.
19. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, Ghossein RA, Fagin JA 2009 Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3- CA, and AKT1. Cancer Res 69:4885-4893.
20. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH 2009 Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684.
21. Horak CE, Lee JH, Marshall JC, Shreeve SM, Steeg PS 2008 The role of metastasis suppressor genes in metastatic dormancy. APMIS 116:586-601.
22. Zafon C, Obiols G, Castellvi J, Tallada N, Galofre P, Gemar E, Mesa J, Simo R 2001 nm23-H1 immunoreactivity as a prognostic factor in differentiated thyroid carcinoma. J Clin Endocrinol Metab 86:3975-3980. (Pubitemid 32756007)
23. Arai T, Watanabe M, Onodera M, Yamashita T, Masunaga A, Itoyama S, Itoh K, Sugawara I 1993 Reduced nm 23-H1 messenger RNA expression in metastatic lymph nodes from patients with papillary carcinoma of the thyroid. Am J Pathol 142:1938-1944. (Pubitemid 24057088)
24. Arai T, Yamashita T, Urano T, Masunaga A, Itoyama S, Itoh K, Shiku H, Sugawara I 1995 Preferential reduction of nm23-H1 gene product in metastatic tissues from papillary and follicular carcinomas of the thyroid. Mod Pathol 8: 252-256.
25. Ringel MD, Hardy E, Bernet VJ, Burch HB, Schuppert F, Burman KD, Saji M 2002 Metastin receptor is overexpressed in papillary thyroid cancer and activates MAP kinase in thyroid cancer cells. J Clin Endocrinol Metab 87:2399-2402. (Pubitemid 34521537)
26. Stathatos N, Bourdeau I, Espinosa AV, Saji M, Vasko VV, Burman KD, Stratakis CA, Ringel MD 2005 KiSS-1/G protein-coupled receptor 54 metastasis suppressor pathway increases myocyte-enriched calcineurin interacting protein 1 expression and chronically inhibits calcineurin activity. J Clin Endocrinol Metab 90:5432-5440. (Pubitemid 41262312)
27. Espinosa AV, Shinohara M, Porchia LM, Chung YJ, McCarty S, Saji M, Ringel MD 2009 Regulator of calcineurin 1 modulates cancer cell migration in vitro. Clin Exp Metastasis 26:517-526.
28. Bodenstine TM, Welch DR 2008 Metastasis suppressors and the tumor microenvironment. Cancer Microenviron 1:1-11.
29. Nash KT, Phadke PA, Navenot J-M, Hurst DR, Accavitti- Loper MA, Sztul E, Vaidya KS, Frost AR, Kappes JX, Peiper SC, Welch DR 2007 Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy. J Natl Cancer Inst 99:309-321. (Pubitemid 47078727)
30. Ryeom S, Baek K-H, Rioth MJ, Lynch RC, Zaslavsky A, Birsner A, Yoon SS, McKeon F 2008 Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth. Cancer Cell 13:420-431. (Pubitemid 351609439)
31. Minami T, Yano K, Miura M, Kobayashi M, Suehiro J, Reid PC, Hamakubo T, Ryeom S, Aird WC, Kodama T 2009 The Down syndrome critical region gene 1 short variant promoters direct vascular bed-specific gene expression during inflammation in mice. J Clin Invest 119:2257-2270.
32. Baek KH, Zaslavsky A, Lynch RC, Britt C, Okada Y, Siarey RJ, Lensch MW, Park IH, Yoon SS, Minami T, Korenberg JR, Folkman J, Daley GQ, Aird WC, Galdzicki Z, Ryeom S 2009 Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature 459:1126-1130.
33. Iiizumi M, Bandyopadhyay S, Watabe K 2007 Interaction of Duffy antigen receptor for chemokines and KAI1: a critical step in metastasis suppression. Cancer Res 67:1411-1414. (Pubitemid 46383363)
34. Reddy KB, Nabha SM, Atanaskova N 2003 Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev 22:395-403. (Pubitemid 36791895)
35. Keith B, C. S 2007 Hypoxia-inducible factors, stem cells, and cancer. Cell 129:465-472.
36. Sherman SI 2009 Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 94:1493-1499.
37. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS 2009 Accelerated metastasis after shortterm treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232-239.
38. Barkan D, Green JE, Chambers AF Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur J Cancer 46:1181-1188.
39. Nazarenko I, Rana S, Baumann A, McAlear J, Hellwig A, Trendelenburg M, Lochnit G, Preissner KT, Zoller M 2010 Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Res 70:1668-1678.
40. Barkan D, Kleinman H, Simmons JL, Asmussen H, Kamaraju AK, Hoenorhoff MJ, Liu ZY, Costes SV, Cho EH, Lockett S, Khanna C, Chambers AF, Green JE 2008 Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res 68: 6241-6250.
41. Friedl P 2004 Prespecification and plasticity: shifting mechanisms of cell migration. Curr Opin Cell Biol 16:14-23. (Pubitemid 38368147)
42. Baker EL, Bonnecaze RT, Zaman MH 2009 Extracellular matrix stiffness and architecture govern intracellular rheology in cancer. Biophys J 97:1013-1021.
43. Vasko V, Espinosa AV, Scouten W, He H, Auer H, Liyanarachchi S, Larin A, Savchenko V, Francis GL, de la Chapelle A, Saji M, Ringel MD 2007 Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci U S A 104:2803-2808. (Pubitemid 46327960)
44. Riesco-Eizaguirre G, Rodriguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M, Santisteban P 2009 The BRAFV600E oncogene induces transforming growth factor {beta} secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res 69:8317-8325.
45. Nowicki TS, Kummer NT, Iacob C, Suslina N, Schaefer S, Schantz S, Shin E, Moscatello AL, Tiwari RK, Geliebter J 2010 Inhibition of uPAR and uPA reduces invasion in papillary thyroid carcinoma cells. Laryngoscope 120:1383-1390.
46. Schweppe RE, Kerege AA, French JD, Sharma V, Grzywa RL, Haugen BR 2009 Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer. J Clin Endocrinol Metab 94:2199-2203.
47. McCarty SK, Saji M, Zhang X, Jarjoura D, Fusco A, Vasko VV, Ringel MD Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion. Endocr Relat Cancer 17:989-999.
48. Farrar JD, Katz KH, Windsor J, Thrush G, Scheuermann RH, Uhr JW, Street NE 1999 Cancer dormancy. VII. A regulatory role for CD8? T cells and IFN-gamma in establishing and maintaining the tumor-dormant state. J Immunol 162:2842-2849. (Pubitemid 29309310)
49. Wieder T, Braumuller H, Kneilling M, Pichler B, Rocken M 2008 T cell-mediated help against tumors. Cell Cycle 7:2974-2977.
50. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME 2008 Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8:299-308. (Pubitemid 351430867)
51. Guarino V, Castellone MD, Avilla E, Melillo RM 2010 Thyroid cancer and inflammation. Mol Cell Endocrinol 321:94-102.
52. Muzza M, Degl?Innocenti D, Colombo C, Perrino M, Ravasi E, Rossi S, Cirello V, Beck-Peccoz P, Borrello MG, Fugazzola L 2010 The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies. Clin Endocrinol 72:702-708.
53. French JD, Weber ZJ, Fretwell DL, Said S, Klopper JP, Haugen BR 2010 Tumor-associated lymphocytes and increased FoxP3? regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab 95:2325-2333.
54. de Visser KE, Eichten A, Coussens LM 2006 Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6:24-37. (Pubitemid 43053650)
55. Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA 2008 Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer 15:1069-1074.
56. Pufnock JS, Rothstein JL 2009 Oncoprotein signaling mediates tumor-specific inflammation and enhances tumor progression. J Immunol 182:5498-5506.
57. Aldrich JF, Lowe DB, Shearer MH, Winn RE, Jumper CA, Kennedy RC 2010 Vaccines and immunotherapeutics for the treatment of malignant disease. Clin Dev Immunol [EPub ahead of print].
58. Peinado H, Lavotshkin S, Lyden D 2011 The secreted factors responsible for pre-metastatic niche formation: Old sayings and new thoughts. Semin Cancer Biol [EPub ahead of print].
59. Al-Nedawi K, Meehan B, Rak J 2009 Microvesicles: messengers and mediators of tumor progression. Cell Cycle 8:2014-2018.
60. Ostrowski M, Carmo NB, Krumeich S, Fanget I, Raposo G, Savina A, Moita CF, Schauer K, Hume AN, Freitas RP, Goud B, Benaroch P, Hacohen N, Fukuda M, Desnos C, Seabra MC, Darchen F, Amigorena S, Moita LF, Thery C 2010 Rab27a and Rab27b control different steps of the exosome secretion pathway. Nature Cell Biol 12:19-30; sup pp 11-13.
61. Simons M, Raposo G 2009 Exosomes-vesicular carriers for intercellular communication. Curr Opin Cell Biol 21: 575-581.
62. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A, Rak J 2008 Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nature Cell Biol 10:619-624. (Pubitemid 351627382)
63. Thery C, Amigorena S, Raposo G, Clayton A 2006 Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol Chapter 3:Unit 3.22.